Big Money Sentiment decreased to 1.06 in Q4 2018. It has change of 0.23, from 2018Q3’s 1.29. The ratio fall due to Galectin Therapeutics, Inc. positioning: 8 sold and 10 reduced. 10 funds bought stakes and 9 increased stakes. Investors holded 5.15 million in 2018Q3 but now own 4.77 million shares or 7.28% less.
Boothbay Fund Mgmt Ltd Limited Liability Company stated it has 30,562 shs or 0.02% of all its holdings. Bank & Trust Of New York Mellon Corp owns 19,930 shs. 20 were reported by Optimum Investment Advsr. California Public Employees Retirement Sys invested 0% of its capital in Galectin Therapeutics, Inc. (NASDAQ:GALT). Da Davidson Co accumulated 718,923 shs. 62,205 are owned by Morgan Stanley. Cwm Ltd stated it has 2,000 shs or 0% of all its holdings. Susquehanna Interest Grp Inc Limited Liability Partnership owns 0% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 163,109 shs. Tci Wealth Advsr Inc reported 300 shs or 0% of all its holdings. Texas-based Next Financial Grp has invested 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). State Street has invested 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Lpl Fin Lc reported 0% of its capital in Galectin Therapeutics, Inc. (NASDAQ:GALT). Blackrock reported 0% of its capital in Galectin Therapeutics, Inc. (NASDAQ:GALT). Cetera Advisor Network Ltd Limited Liability Company holds 19,021 shs or 0% of its capital. Pnc Finance Services Grp holds 0% or 47,164 shs in its capital.

Galectin Therapeutics, Inc. had 1 sale and 5 insider purchases since September 7, 2018. This’s net activity of $128,476. Uihlein Richard E bought $250,559 worth of stock or 51,500 shs. $116,585 worth of Galectin Therapeutics, Inc. (NASDAQ:GALT) shs were sold by OMENN GILBERT S. AMELIO GILBERT F sold $150,000 worth of stock or 30,000 shs. $12,200 worth of Galectin Therapeutics, Inc. (NASDAQ:GALT) shs were bought by ELDRED KARY. FREEMAN KEVIN D bought $6,428 worth of stock.

On April, 4 WallStreet awaited Galectin Therapeutics, Inc. (NASDAQ:GALT)’s earnings release, Faxor reports. The earnings per share diference is $0.01 or 14.29 % down from last years number. Previous year: $-0.07; Analysts forcast: $-0.08. 14.29 % negative EPS growth is what analysts predict. $-0.07 earnings per share was published for previous quarter. GALT is hitting $4.73 during the last trading session, after decreased 4.06%.Currently Galectin Therapeutics, Inc. is uptrending after 31.58% change in last March 10, 2018. GALT has also 230,396 shares volume. GALT outperformed the S&P 500 by 27.21%.

Galectin Therapeutics, Inc. (NASDAQ:GALT) Ratings Coverage

In total 2 analysts cover Galectin Therapeutics (NASDAQ:GALT). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 4 are the (NASDAQ:GALT)’s analyst reports since February 13, 2019 according to StockzIntelligence Inc. On Thursday, March 7 the firm has “Buy” rating given by H.C. Wainwright. On Thursday, March 7 the firm earned “Buy” rating by FBR Capital.

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer.The firm is worth $194.83 million. The company's lead product candidate includes galectin-3 inhibitor , a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer.Last it reported negative earnings. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis.

For more Galectin Therapeutics, Inc. (NASDAQ:GALT) news announced recently go to: Streetinsider.com, Seekingalpha.com, Seekingalpha.com, Seekingalpha.com or Globenewswire.com. The titles are as follows: “Galectin Therapeutics (GALT) Names Harold H. Shlevin as New CEO; Peter G. Traber Resigns – StreetInsider.com” announced on June 12, 2018, “Your Daily Pharma Scoop: Galectin Phase 3 Trial, Acer NDA, Chiasma SPA Amendments – Seeking Alpha” on May 15, 2018, “Galectin to advance NASH candidate GR-MD-02 into Phase 3 – Seeking Alpha” with a publish date: May 14, 2018, “NASH Cirrhosis: The Real NASH Epidemic – Seeking Alpha” and the last “Galectin Therapeutics Late-Breaker Presentation at The International Liver Congress Reinforces and Extends the Positive Effects of GR-MD-02 in Patients With NASH Cirrhosis – GlobeNewswire” with publication date: April 16, 2018.